Literature DB >> 30060216

Hepatitis C virus infection and the kidney.

Meghan E Sise1.   

Abstract

Entities:  

Year:  2018        PMID： 30060216      PMCID： PMC6399482          DOI： 10.1093/ndt/gfy230

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  16 in total

1.  Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients.

Authors:  David S Goldberg; Peter L Abt; Emily A Blumberg; Vivianna M Van Deerlin; Matthew Levine; K Rajender Reddy; Roy D Bloom; Susanna M Nazarian; Deirdre Sawinski; Paige Porrett; Ali Naji; Richard Hasz; Lawrence Suplee; Jennifer Trofe-Clark; Anna Sicilia; Maureen McCauley; Midhat Farooqi; Caren Gentile; Jennifer Smith; Peter P Reese
Journal:  N Engl J Med       Date:  2017-04-30       Impact factor: 91.245

2.  Meta-analysis of observational studies: hepatitis C and survival after renal transplant.

Authors:  F Fabrizi; P Martin; V Dixit; P Messa
Journal:  J Viral Hepat       Date:  2013-07-30       Impact factor: 3.728

3.  Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis.

Authors:  David A Goodkin; Brian Bieber; Michel Jadoul; Paul Martin; Eiichiro Kanda; Ronald L Pisoni
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-01       Impact factor: 8.237

4.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.

Authors:  Miklos Z Molnar; Hazem M Alhourani; Barry M Wall; Jun L Lu; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

Review 5.  Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.

Authors:  Tao Li; Yundong Qu; Ying Guo; Yan Wang; Lei Wang
Journal:  Liver Int       Date:  2017-01-02       Impact factor: 5.828

6.  Hepatitis C infection is very rarely treated among hemodialysis patients.

Authors:  David A Goodkin; Brian Bieber; Brenda Gillespie; Bruce M Robinson; Michel Jadoul
Journal:  Am J Nephrol       Date:  2013-10-29       Impact factor: 3.754

7.  KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD.

Authors:  Craig E Gordon; Ethan M Balk; Bryan N Becker; Peter A Crooks; Bertrand L Jaber; Cynda A Johnson; Maureen A Michael; Brian J G Pereira; Katrin Uhlig; Adeera Levin
Journal:  Am J Kidney Dis       Date:  2008-11       Impact factor: 8.860

8.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

Authors:  Edward Gane; Eric Lawitz; David Pugatch; Georgios Papatheodoridis; Norbert Bräu; Ashley Brown; Stanislas Pol; Vincent Leroy; Marcello Persico; Christophe Moreno; Massimo Colombo; Eric M Yoshida; David R Nelson; Christine Collins; Yang Lei; Matthew Kosloski; Federico J Mensa
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

Review 9.  Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.

Authors:  Susan J Bersoff-Matcha; Kelly Cao; Mihaela Jason; Adebola Ajao; S Christopher Jones; Tamra Meyer; Allen Brinker
Journal:  Ann Intern Med       Date:  2017-04-25       Impact factor: 25.391

10.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Authors:  David Roth; David R Nelson; Annette Bruchfeld; AnnMarie Liapakis; Marcelo Silva; Howard Monsour; Paul Martin; Stanislas Pol; Maria-Carlota Londoño; Tarek Hassanein; Philippe J Zamor; Eli Zuckerman; Shuyan Wan; Beth Jackson; Bach-Yen Nguyen; Michael Robertson; Eliav Barr; Janice Wahl; Wayne Greaves
Journal:  Lancet       Date:  2015-10-05       Impact factor: 202.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.